AU2013269120B2 - Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein - Google Patents

Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein Download PDF

Info

Publication number
AU2013269120B2
AU2013269120B2 AU2013269120A AU2013269120A AU2013269120B2 AU 2013269120 B2 AU2013269120 B2 AU 2013269120B2 AU 2013269120 A AU2013269120 A AU 2013269120A AU 2013269120 A AU2013269120 A AU 2013269120A AU 2013269120 B2 AU2013269120 B2 AU 2013269120B2
Authority
AU
Australia
Prior art keywords
peptide
amino acid
formula
immunogenic compound
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013269120A
Other languages
English (en)
Other versions
AU2013269120A1 (en
Inventor
Joel Crouzet
Dominique Desfontaines
Raphael Ho Tsong Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNAVIRVAX
Original Assignee
INNAVIRVAX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNAVIRVAX filed Critical INNAVIRVAX
Publication of AU2013269120A1 publication Critical patent/AU2013269120A1/en
Application granted granted Critical
Publication of AU2013269120B2 publication Critical patent/AU2013269120B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K16/1145—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2013269120A 2012-05-31 2013-05-30 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein Active AU2013269120B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
EP12305602.0 2012-05-31
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (2)

Publication Number Publication Date
AU2013269120A1 AU2013269120A1 (en) 2014-12-18
AU2013269120B2 true AU2013269120B2 (en) 2017-04-20

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013269120A Active AU2013269120B2 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein

Country Status (21)

Country Link
US (1) US9511136B2 (cg-RX-API-DMAC7.html)
EP (2) EP2668959B1 (cg-RX-API-DMAC7.html)
JP (1) JP6352251B2 (cg-RX-API-DMAC7.html)
KR (1) KR102077876B1 (cg-RX-API-DMAC7.html)
CN (1) CN104507496B (cg-RX-API-DMAC7.html)
AU (1) AU2013269120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029861B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875162C (cg-RX-API-DMAC7.html)
DK (1) DK2668959T3 (cg-RX-API-DMAC7.html)
EA (1) EA027803B1 (cg-RX-API-DMAC7.html)
ES (2) ES2528109T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150058T1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10128A (cg-RX-API-DMAC7.html)
MX (1) MX360206B (cg-RX-API-DMAC7.html)
PL (1) PL2668959T3 (cg-RX-API-DMAC7.html)
PT (1) PT2668959E (cg-RX-API-DMAC7.html)
RS (1) RS53769B1 (cg-RX-API-DMAC7.html)
SI (1) SI2668959T1 (cg-RX-API-DMAC7.html)
UA (1) UA118542C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013179262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409023B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
TWI740823B (zh) * 2015-04-17 2021-10-01 澳大利亞商保健樂科技昆士蘭有限公司 疫苗組成物及其用途
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
TWI379839B (en) * 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG HAI-LONG ET AL: "A novel combined conjugate vaccine: Enhanced immunogenicity of bFGF with CRM197 as a carrier protein", MOLECULAR MEDICINE REPORTS, vol. 4, no. 5, September 2011 (2011-09), pages 857-863. *

Also Published As

Publication number Publication date
KR20150032266A (ko) 2015-03-25
US9511136B2 (en) 2016-12-06
MX360206B (es) 2018-10-24
PL2668959T3 (pl) 2015-04-30
CN104507496A (zh) 2015-04-08
EP2854846A1 (en) 2015-04-08
WO2013179262A1 (en) 2013-12-05
AU2013269120A1 (en) 2014-12-18
PT2668959E (pt) 2015-02-05
CA2875162C (en) 2021-09-14
ES2528109T3 (es) 2015-02-04
BR112014029861A2 (pt) 2017-07-25
IN2014DN10128A (cg-RX-API-DMAC7.html) 2015-08-21
UA118542C2 (uk) 2019-02-11
KR102077876B1 (ko) 2020-02-14
EP2668959A1 (en) 2013-12-04
US20150147348A1 (en) 2015-05-28
EA201491969A1 (ru) 2015-04-30
RS53769B1 (sr) 2015-06-30
CN104507496B (zh) 2018-08-03
EA027803B1 (ru) 2017-09-29
JP6352251B2 (ja) 2018-07-04
HRP20150058T1 (hr) 2015-04-10
ZA201409023B (en) 2016-08-31
ES2701084T3 (es) 2019-02-20
MX2014014526A (es) 2015-06-02
EP2854846B1 (en) 2018-09-12
CA2875162A1 (en) 2013-12-05
SI2668959T1 (sl) 2015-03-31
DK2668959T3 (en) 2015-01-26
JP2015519359A (ja) 2015-07-09
BR112014029861B1 (pt) 2022-05-24
EP2668959B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
AU2013269120B2 (en) Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
EP2758038B1 (en) Novel influenza hemagglutinin protein-based vaccines
US10596238B2 (en) Methods and compositions related to immunogenic fibrils
JP2012500829A (ja) Ｃｂｄ１エピトープにおけるオーバーラップする中和決定基に対応する合成ペプチドによって広域中和抗体が誘導される
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
WO2016184962A1 (en) Treatment of hiv-infected individuals
WO2016184973A1 (en) Treatment of hiv-infected individuals
WO2012050893A2 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein
WO2022242432A1 (en) Peptide vaccine for virus infection
JP2010500407A (ja) Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
JP2001505763A (ja) Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
KR102301961B1 (ko) 아밀로이드 접합체 및 그의 용도 및 방법
JP2009536653A (ja) Ｈｉｖ−１免疫原性組成物
JP2003533542A (ja) Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
WO2012140424A2 (en) Composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)